louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01468415: Efficiency Comparison Between Methylprednisolone and Phenol 8% Treatment Using a Trans Sacral Approach - on Lower Back Pain and Limbs
Official title: Efficiency Comparison Between Methylprednisolone and Phenol 8% Treatment Using a Trans Sacral Approach - on Lower Back Pain and Limbs
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Back Pain
Keywords: Methylprednisolone
trans sacral block
phenol
Lead sponsor: Assaf-Harofeh Medical Center
Sponsor class: OTHER_GOV
First posted: 2011-11-09
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The American Society of Anesthesiologists Task Force on Management, Chronic Pain section, recommended Phenol neurolysis when other techniques have failed to provide adequate pain control. In this study we sought to Compare the pain relieve on a Lower Back and Limbs obtained from Methylprednisolone and Phenol 8% Treatment given by Trans Sacral Approach. The study includes patients who suffers from a chronic low back and/or limbs pain which were referred to be given epidural as a treatment. Control group receives 80 mg Methylprednisolone while the test group receives phenol 8%.


Eligibility criteria: Inclusion Criteria: -at least 18 years of age;

* chronic low back pain of at least 12 weeks duration;
* patients which were diagnosed as a candidate for epidural since other techniques have failed to provide adequate pain control
* Sciatica due to Lumbar Disc Herniation
* Neurogenic Claudication due to Lumbar Spinal Stenosis

Exclusion Criteria:

* patients with unbalanced high blood pressure
* patients who can not ley prone
* patients who consumes anti-clotting medications
* patients with bleeding problems
* patients with Diabetes
* patients who suffers from chronic non-specific lower back and limb pain

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Zerifin
country: Israel
facility: Assaf Harofeh Medical Center
Study officials:
References:
Clinical trial NCT05573815: Evaluation of Clinical Decision Support System for Brain Metastasis Using Brain MR Images
Official title: An Open Label, Single-Center and Random-Selection Retrospective Pivotal Study of Clinical Decision Support System for Brain Metastasis Using Brain MR Images
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Brain Metastases
Lead sponsor: Heuron Inc.
Sponsor class: INDUSTRY
First posted: 2022-10-10
Enrollment: 558
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: BT-M01 is a software that has been pre-learned based on a brain metastasis detection model using brain MR images, and clinical decision support system for brain metastasis by automatically analyzing brain MR images by assisting the medical team.

The specific aims of this study are to evaluate efficacy of BT-M01 for brain metastasis compared to the sensitivity and false positive rates of radiologists group.


Eligibility criteria: Inclusion Criteria:

* Adults over 19 years old
* Brain MR acquired
* Positive group: A patient diagnosed with brain metastasis after a brain MR
* Negative group: A normal person or a patient not diagnosed with brain metastasis after a brain MR

Exclusion Criteria:

* Poor or incomplete brain MR image quality
* A patient with other pathological lesion in brain
* A patients with a history of primary brain tumors

Primary outcomes:
measure: Sensitivity and false positive rates of BT-M01
timeFrame: Within 4 weeks after enrollment
Secondary outcomes:
measure: Positive predictive values of BT-M01
timeFrame: Within 4 weeks after enrollment
measure: Sensitivity and Positive predictive values of BT-M01 by primary cancer
timeFrame: Within 4 weeks after enrollment
measure: Dice coefficient of BT-M01
timeFrame: Within 4 weeks after enrollment
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
state: Song-pa Gu
Study officials:
affiliation: Asan Medical Center
name: Ji Eun Park, M.D.pH.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06875115: Evaluation of the Efficacy of Laser Acupuncture on Uremic Pruritus
Official title: Evaluation of the Efficacy of Laser Acupuncture on Uremic Pruritus-Randomized Controlled Trial Double Blind
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Uremia
Keywords: uremia
Lead sponsor: Dalin Tzu Chi General Hospital
Sponsor class: OTHER
First posted: 2025-03-13
Enrollment: 60
Sex: ALL
Minimum age (years): 20
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Sixty patients were randomly assigned to either the experimental group (n=30) receiving laser acupuncture or the control group (n=30) receiving sham laser acupuncture. Treatment sessions were conducted during dialysis sessions. The experimental group received laser acupuncture at Xuehai, Quchi, and Bai Chongwo acupoints three times per week for four weeks. The control group received sham laser acupuncture at the same acupoints. The 5-D Pruritus Scale and DLQI were used to assess pruritus severity before and after the intervention.

Detailed description: The subjects were divided into two groups to investigate whether laser acupuncture can improve uremic pruritus.

Eligibility criteria: Inclusion Criteria:

* Age ≥ 20 years.
* Intact parathyroid hormone (iPTH) levels \< 68 pg/mL (patients with -thyroidectomy excluded).
* Urea nitrogen (BUN) clearance rate (Kt/V) ≥ 1.2 at each dialysis session.
* Serum phosphate levels \< 5.5 mg/dL.
* Receiving hemodialysis three times weekly for at least three consecutive months.
* No history of acute illnesses like infections or cardiovascular disease.
* Avoiding a high-phosphorus diet.
* Adjusting dialysate calcium concentration to 8.6-10 mg/dL.
* Replacing the artificial kidney or increasing dialysis blood flow

Exclusion Criteria:

* Pregnant or nursing.
* History of photosensitivity.
* Recent use of systemic or local medications for pruritus (e.g., immunosuppressants, opioid agonists/antagonists, glucocorticoids, antihistamines, ultraviolet B therapy).
* Hepatobiliary dysfunction based on medical history and liver function tests.
* Malignancies.
* Other itchy skin conditions diagnosed by a dermatologist.
* Wounds near acupuncture points, contraindicating laser acupuncture

Primary outcomes:
measure: Title: Evaluation of the efficacy of laser acupuncture on ureimc pruritus
timeFrame: A 4-week timeframe from enrollment to treatment completion.
Secondary outcomes:
Other outcomes:
Locations:
city: Dalin
country: Taiwan
facility: Dalin Tzu Chi Hospital
state: Chiayi
Study officials:
affiliation: doctor
name: Ying-HSU Juan, doctor
role: STUDY_CHAIR
References:
Clinical trial NCT04058015: Outcome of Patients With Thoraco-abdominal Injury and Stress-induced Hyperglycemia or Diabetic Hyperglycemia
Official title: Admission Hyperglycemia in Patients With Moderate to Severe Thoracoabdominal Injuries is Associated With Higher Mortality Rate Than Non-Diabetic Normoglycemic Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Abdominal Injury
Thoracic Injury
Hyperglycemia
Hyperglycemia Stress
Keywords: admission hyperglycemia
stress-induced hyperglycemia
diabetic hyperglycemia
diabetes mellitus
thoracoabdominal trauma
mortality
Lead sponsor: Chang Gung Memorial Hospital
Sponsor class: OTHER
First posted: 2019-08-15
Enrollment: 802
Sex: ALL
Minimum age (years): 20
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: This retrospective study reviewed data from trauma patients registered between January 1, 2009 and December 31, 2018. The inclusion criteria were age ≥20 years Adult patients with moderate to severe thoracoabdominal injuries (n = 802) were grouped into four exclusive subgroups: (1) SIH, which was defined as a serum glucose ≥ 200 mg/dL in the patients without DM (n = 52); (2) DH, which indicated a serum glucose ≥ 200 mg/dL in patients with DM (n = 79); (3), DN, which was defined when there was a serum glucose \< 200 mg/dL in the patients with DM (n = 50); and (4) NDN, indicating a serum glucose \< 200 mg/dL in patients who were absent of DM (n = 621)

Brief summary: This study aimed to measure the effects of SIH and DH on the mortality outcomes of the adult patients with moderate to severe thoracoabdominal injury

Detailed description: Because the pathophysiologic response of the patients with a thoracoabdominal injury is different from those who had a traumatic brain injury, this study aimed to measure the effects of hyperglycemia induced by stress or by diabetes on the outcomes of patients with thoracoabdominal injuries in comparison with those who had non-diabetic normoglycemia (NDN). The primary study hypothesis stated that, following thoracoabdominal injuries, the patients with SIH had a worse outcome than patients with DH. The primary outcome was mortality rate of these patients.

Eligibility criteria: Inclusion Criteria:

* adult patients with moderate to severe thoracoabdominal injuries

Exclusion Criteria:

* patients with a thoracic and abdominal abbreviated injury scale (AIS) \< 3
* patients who had polytrauma which was defined as there was additional AIS scores ≥ 3 points in other regions of the body
* patients less than 20 years old
* patients who had sustained a burn injury

Primary outcomes:
measure: in-hospital mortality
timeFrame: up to 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Kaohsiung
country: Taiwan
facility: Kaohsiung Chang Gung Memorial Hospital
Study officials:
affiliation: Chang Gung Memorial Hospital
name: TSANG-TANG Hsieh
role: STUDY_CHAIR
References:
Clinical trial NCT03324815: Methadone Associated With Morphine for Cancer Pain
Official title: Analgesic Effect Evaluation of Methadone Associated With Morphine for Cancer Pain: Prospective Randomized Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Cancer
Keywords: Morphine
Methadone
Pain
Lead sponsor: Federal University of São Paulo
Sponsor class: OTHER
First posted: 2017-10-30
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study was prospective, randomized. Patients with cancer pain were evaluated, one group receiving methadone with morphine and another group receiving morphine as the only opioid. Pain intensity, total morphine dose and adverse effects were evaluated.

Detailed description: Opioids are the most important analgesics for the relief of cancer pain. In addition tolerance and hyperalgesia may ocurr as a consequence of treatment with these drugs. Medications for pain relief may also cause increased pain. NMDA receptor blockers may prevent or reduce the development of hyperalgesia. Methadone is a weak NMDA receptor antagonist and therefore its association could prevent hyperalgesia. The primary endpoint of the study was whether the administration of low dose methadone associated with morphine promotes better analgesic effect in patients with cancer pain, And secondarily to assess whether there is a reduction in the total dose of opioid needed for pain relief, and whether reduction of the opioid-related adverse effects occurs.

Eligibility criteria: Inclusion Criteria:

* Approved by the Ethics Committee
* signed the informed consent
* cancer pain
* starting the WHO thirth analgesic ladder,

Exclusion Criteria:

* cognitive impairment
* psychiatric disease
* illicit drug user
* hypersensitivity to the study drugs
* pregnant

Primary outcomes:
measure: Opioid consumption
timeFrame: 3 months
Secondary outcomes:
measure: Pain intensity
timeFrame: 3 months
Other outcomes:
Locations:
city: São Paulo
country: Brazil
facility: Rioko K Sakata
Study officials:
affiliation: Universidade Federal de São Paulo
name: Rioko K Sakata, MD; PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Duarte FCN, Ferraro LHDC, Ferreira A, Sakata RK. A Randomized Controlled Trial Evaluating the Analgesic Effect of the Combination of Methadone With Morphine for Cancer Related Pain. Clin J Pain. 2021 Sep 1;37(9):664-668. doi: 10.1097/AJP.0000000000000959.
Clinical trial NCT02813915: Non-invasive Cardiac Output Monitor in Young Adults
Official title: A Trial of a Non-Invasive Cardiac Output in Young Adults
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Fluid Overload
Hypovolemia
Keywords: cardiac monitoring, Cheetah Medical, passive leg raises
Lead sponsor: Indiana University
Sponsor class: OTHER
Collaborators: name: Cheetah Medical Inc.
First posted: 2016-06-27
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients 18-30 years of age having surgery at Riley or University Hospital

Brief summary: The investigators would like to study cardiac output, stroke volume, and fluid responsiveness on young adult pediatric patients undergoing anesthesia and surgery with the use of the NICOM, a non-invasive monitor. The NICOM method is non-invasive and provides reliable trending of cardiac output and stroke volume. Measuring cardiac output in conjunction with routine monitoring will provide a better assessment of intra-operative status.

Detailed description: This study will involve measurements of cardiac output, stroke volume, and fluid responsiveness (change in stroke volume of ≥ 10%) obtained via passive leg raise (PLR) before and after anesthesia induction.

Eligibility criteria: Inclusion Criteria:

* 18 -30 years of age
* presenting for surgery at Riley or University Hospital

Exclusion Criteria:

* younger than 18
* severely mentally handicapped
* orthopedic cases with leg injuries
* any other contraindications that would prevent or discourage passive leg raises
* if deemed ineligible by an investigator for any other reason.

Primary outcomes:
measure: Patient Fluid responsiveness
timeFrame: within 30 minutes post-anesthesia induction
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Indiana University
name: Andrew Stasic, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05486715: Vitamin d Level and it's Association With Disease Activity in Egyptian Rheumatoid Arthritis Patients
Official title: Vitamin d Level and it's Association With Disease Activity in Egyptian Rheumatoid Arthritis Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Rheumatoid Arthritis (RA)
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2022-08-03
Enrollment: 130
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Sample size was calculated using Epi- Info7. Based on previous study the prevalence of vitamin D insufficiency and deficiency in RA patients was 56% (Cesshetti 2016. ). With a confidence limits of 8% and a confidence level of 80% the minimum number of patients required for this study is 65 patients RA and 65 of healthy

Brief summary: Vitamin D level and its association with disease activity in Egyptian Rheumatoid arthritis (RA) patients

Detailed description: Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects about 1% of the human population. Its incidence increases between 25 and 55 years and is the most common type of chronic inflammatory arthritis . It affects joints bilaterally with synovial hyperplasia, cartilage erosion, bone destruction, and progressive loss of function . also characterized by systemic features and joint involvement. It can lead to significant morbidity and mortality so early diagnosis and proper treatment are crucial in decreasing the burden of this disease . According to the World Health Organization mortality database of 31 countries, RA accounts for almost 18% of all deaths caused by different types of arthritis and other musculoskeletal diseases, but the exact cause of RA remains unknown

Eligibility criteria: Inclusion Criteria:

* Both males and females in the age group of 1875 years having RA according to the American College of Rheumatology European League Against Rheumatism 2010 criteria (Meena et al., 2018). Will enrolled in this study

Exclusion Criteria:

* Patients with malnutrition, hepatic and renal dysfunction, hyperparathyroidism, hyperthyroidism, diabetes mellitus, and patients on Vitamin D supplementation in the past 6 months or on medications that can affect bone and Vitamin D metabolism (anticonvulsants, diuretics, and thyroxin) were excluded from this study.
* Patients with overlap syndrome
* known allergy to DMARDs, 1,25 dihydroxy vitamin D3 or calcium supplements

Primary outcomes:
measure: prevalence of vitamin D dificency in Rheumatoid arthritis
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Assiut University
name: Essam Ab Elmohsen
role: STUDY_DIRECTOR
References:
Clinical trial NCT04294615: Clinical Response and Safety Following FMT for UC
Official title: Clinical Response and Safety Following Fecal Microbiota Transplantation by Automatic Methods in Patients With Moderate-Severe Active Ulcerative Colitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Inflammatory Bowel Diseases
Fecal Microbiota Transplantation
Lead sponsor: Air Force Military Medical University, China
Sponsor class: OTHER
First posted: 2020-03-04
Enrollment: 9
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study aims to evaluate the clinical efficacy and safety of fecal microbiota transplantation by automatic methods in the treatment of moderate to severe active ulcerative colitis. There are two groups according to FMT pathway ( through a naso-jejunal tube or transendoscopic enteral tubing). Patients were followed up until 2 weeks after the final FMT in hospital.


Eligibility criteria: Inclusion Criteria:

- Eligible patients required a diagnosis of ulcerative colitis made by a primary gastroenterologist based upon history, physical exam, laboratory/radiological studies and gastrointestinal histology. All patients were age ≥ 18 year old at the time of enrollment. They had moderate to severe symptoms with a mayo score between 6\~12 and an endoscopic subscore ≥2. Patient medication for UC could not have changed for at least one month prior to FMT.

Exclusion Criteria:

- Active or history of intraabdominal abscess, acute abdomen or other clinical emergencies requiring emergent management, pregnancy, prior history of FMT, prior history of TNF inhibitors use, or other serious systemic disease.

Primary outcomes:
measure: clinical response
timeFrame: 2 weeks after FMT
Secondary outcomes:
measure: clinical remission, safety and progression of disease
timeFrame: 2 weeks after FMT
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03246815: STD Testing in Outpatient Practices
Official title: STD Testing in Outpatient Practices-The STOP STDs Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: STD
Lead sponsor: University of Pittsburgh
Sponsor class: OTHER
Collaborators: name: CDC Foundation
First posted: 2017-08-11
Enrollment: 6771
Sex: FEMALE
Minimum age (years): 15
Maximum age (years): 24
Standard ages: CHILD
ADULT
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Young women at risk for STDs

Brief summary: National guidelines have recommended routine STD screening (chlamydia and gonorrhea) for sexually active young women under the age of 25. Despite these recommendations, many young women are not being screened for STDs, with some estimates that less than 50% of women receiving health care are screened for chlamydia. Untreated STDs can lead to important sequelae to women's reproductive health including pelvic inflammatory disease, infertility and ectopic pregnancy. One of the most important barriers to widespread STD screening is provider failure to recognize an opportunity for STD screening. The goal of this study is to determine whether offering STD screening (chlamydia and gonorrhea) by a non-physician member of the medical practice (who receives an automated alert indicating STD screening should be offered) will be associated with a higher rate of STD screening in young women attending primary care practices compared to usual care (where a physician offers screening with no electronic alert). This study will be performed in UPMC-affiliated primary care practices (Family Practice, Internal Medicine, OB/GYN, Pediatrics). Practices will be assigned to the intervention or usual care. The intervention will be an auto-task in the electronic medical record to the non-physician/NP/PA medical staff (medical assistants, LPNs, RNs) to offer chlamydia and gonorrhea screening via urine or self-collected vaginal sampling, in an opt-out manner, to eligible women. Practices assigned to the usual care group will not have the intervention. STD screening rates (# women undergoing STD screening/# eligible women) will be compared between the to groups (intervention practices and control practices). Results of this study may be important to guide national STD screening recommendations and will address critical barriers to widespread STD screening.


Eligibility criteria: Inclusion Criteria:

Women ages 15-24 Sexually Active Receiving care in one of the primary care offices affiliated with UPMC selected for this study.

Exclusion Criteria:

Pregnancy

Primary outcomes:
measure: Rate of STD Screening
timeFrame: Day 1
measure: Number of Chlamydia and Gonorrhea infections identified
timeFrame: Day 1
Secondary outcomes:
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: Magee-Womens Hospital of UPMC/associated community clinics
state: Pennsylvania
Study officials:
affiliation: University of Pittsburgh
name: Harold C Wiesenfeld, MD
role: PRINCIPAL_INVESTIGATOR
References: